A-PVP, like other psychostimulants, can cause hyperstimulation, paranoia, and hallucinations. α-PVP has been reported to be the cause, or a significant contributory cause of death in suicides and overdoses caused by combinations of drugs. α-PVP has also been linked to at least one death with pulmonary edema and moderately advanced atherosclerotic coronary disease when it was combined with pentedrone.
In according to Craig Crespi in the journal Case Reports in Psychiatry. Symptoms are know to easily escalate into frightening delusions, paranoid psychosis, extreme agitation. And a multitude of other altered mental states. Common adverse effects of α-PVP are in line with other psychostimulants, and include:
Altered mental state
In addition, agitated delirium may occur as an adverse effect of α-PVP, which carries its own set of symptoms, including anxiety, agitation, violent outbursts, confusion, myoclonus and convulsions, with clinical symptoms including tachycardia, hypertension, diaphoresis, mydriasis and hyperthermia.
α-PVP acts as a norepinephrine-dopamine reuptake inhibitor with IC50 values of 14.2 and 12.8 nM. Respectively, similar to its methylenedioxy derivative MDPV. Similar to other cathinones, α-PVP has been show to have reinforcing effects in rats.
α-PVP gives no reaction with the Marquis reagent. It gives a grey/black reaction with the Mecke reagent.
Detection in body fluids
α-PVP may be quantified in blood, plasma or urine by liquid chromatography-mass spectrometry to confirm a diagnosis of poisoning in hospitalized patients or to provide evidence in a medicolegal death investigation. Blood or plasma α-PVP concentrations are expected to be in a range of 10–50 μg/L in persons using the drug recreationally, >100 μg/L in intoxicated patients and >300 μg/L in victims of acute overdosage.
Society and culture
Hence, α-PVP is a Schedule I drug in New Mexico, Delaware, Florida, Oklahoma, and Virginia. On January 28, 2014, the U.S. DEA listed it, along with nine other synthetic cathinones, on the Schedule 1 with a temporary ban, effective February 27, 2014. The temporary ban was then extend.
As of October 2015, α-PVP is a controlled substance in China.
Italy classified cathinone and all structurally derived analogues (including pyrovalerone analogues) as narcotics on January 2012.
However in Australia Alpha-PVP is a Schedule 9 prohibit substance under the Poisons Standard (July 2016). A Schedule 9 substance is a substance which may be abuse or misuse, the manufacture, possession, sale or use of which should be prohibit by law except when require for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities. The drug was explicitly made illegal in New South Wales after it was illegally market with the imprimatur of erroneous legal advice that it was not encompass by analog provisions of the relevant act. It is encompass by those provisions, and therefore has been illegal for many years in New South Wales. The legislative action follow the death of two individuals from using it; one jumping off a balcony, another having a heart attack after a state of delirium.
Moreover α-PVP is banned in Estonia, Finland, France, Germany, Hungary, Ireland, Latvia, Lithuania, Poland, Romania, Slovenia, Sweden, United Kingdom, Turkey, Norway, as well as the Czech Republic.
Hence, α-PVP is sometimes the active ingredient in recreational drugs sale as “bath salts”. It may also be distinguishes from “bath salts” and sale under a different name: “flakka”, a name use in Florida, or “gravel” in other parts of the U.S. It is reportedly available as cheaply as US$5 per dose. So a laboratory for one county in Florida reported a steady rise in α-PVP detections in seized drugs from none in January–February 2014 to 84 in September 2014.